Good morning. It’s December 24th, and if you’re tired of hearing about GLP-1s at this point, just turn off the TV.

Because 2026 is shaping up to be bigger than 2025.

We’re ending the year with yet another positive trial from Eli Lilly, this time tackling knee pain relief (successfully) along with weight loss.

And if you find yourself hovering over the charcuterie board tomorrow, you’re in luck; that wheel of brie might just be brain food after all.

The rundown for this week:

Let’s get to it. 👇

Yahoo - The 12 longevity trends that doctors are watching in 2026. (Read more)

The Independent - Stuffing your face with cranberries over the holidays? The festive “superfood” is a cancer defender, and heart protector. (Read more)

Vogue - Longevity tourism is on a rocket-ship; take a look inside. (Read more)

Mens Health - White Lotus star, Walter Goggins, is in the best shape of his life at 54. Here’s how he does it. (Read more)

Today Show - A 100-year old gets married, another goes skydiving, and another 101-year old keeps her business running. (Read more)

Press Newsire - FDA approves Novo Nordisk’s Wegovy pill, the first only only oral GLP-1 for weight loss in adults. (Read more)

Eli Lilly’s experimental drug, retatrutide, has set a new benchmark in obesity treatment following a successful late-stage (Phase 3) trial. The weekly injection helped participants with obesity and knee osteoarthritis lose an average of 28.7% of their body weight, roughly 71 pounds, over 68 weeks. This efficacy surpasses that of current market leaders like Zepbound and Wegovy.

Beyond weight loss, the drug showed remarkable benefits for mobility. Participants reported a nearly 76% reduction in knee pain, with more than one in eight becoming completely pain-free by the end of the study.

Retatrutide is nicknamed a "triple G" agonist because it mimics three distinct hormones (GLP-1, GIP, and glucagon) to suppress appetite and burn fat, unlike current drugs that target only one or two.

👉🏾 Learn more about Retatrutride and Eli’ Lilly’s late stage trials

If you’ve ever felt guilty for bypassing the "low-fat" option and reaching straight for the triple-cream brie, science has finally offered you a delicious vindication.

A long-term study recently published in Neurology suggests that high-fat cheese and cream aren’t just good for the soul, they might actually help protect your brain.

Researchers followed over 27,000 people in Sweden for 25 years. They tracked what people ate and who eventually developed dementia.

The results were surprisingly tilted in favor of the cheese lovers.

Those who consumed high-fat cheese (defined as having more than 20% fat) had a 13% lower risk of developing all-cause dementia compared to those who ate little to none. For vascular dementia specifically, the risk dropped by an impressive 29%.

But wait, there’s more!

It wasn't just cheese; high-fat cream showed similar benefits.

People who consumed just a splash a day (about 20g) saw a 16% lower risk of dementia.

Here is the fascinating part: Low-fat dairy showed no such benefit. The protective effects were exclusively linked to the high-fat varieties.

High-fat dairy is rich in fat-soluble vitamins (like A, D, and K2) and specific fatty acids that may support brain health and cardiovascular function.

The fact that the biggest drop was seen in vascular dementia, which is caused by reduced blood flow to the brain, suggests that these fats might be helping keep your neuroplasticity in tip-top shape.

The "protective" amount was about 50g of cheese a day (roughly two slices), so you can stop fearing the fat.

You are now clear to

👉🏾 Go deeper into the study and trial results

The year is ending, and you’ve got big plans for next year.

There will be an onslaught of “new year, new you” advertisements.

Tips and tricks to draw you in and then get you hooked on a monthly subscriptiuon.

Some of it has been validated.

Most of it has not been, atleast over long-term studies.

It’s a good reminder that there is one intervention that has proven to slow aging, and it doesn’t cost you a dime.

A reminder as you kick off 2026…👇🏼